AU Patent

AU2006276246B2 — Novel macrocyclic inhibitors of hepatitis C virus replication

Assigned to Intermune Inc · Expires 2012-09-27 · 14y expired

What this patent protects

The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatiti…

USPTO Abstract

The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Drugs covered by this patent

Patent Metadata

Patent number
AU2006276246B2
Jurisdiction
AU
Classification
—
Expires
2012-09-27
Drug substance claim
No
Drug product claim
No
Assignee
Intermune Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.